Cologuard, a stool DNA test including methylated NDRG4 and BMP3, 7 KRAS mutations with a hemoglobin immunoassay, reported sensitivities of 42.4% for AA, 69.2% for HGD and 92.3% for all stage CRC, and a specificity of 89.8% from 9989 participants [18]. The gene discussed is KRAS; the disease is colorectal carcinoma.